{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-26-000016","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2026-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.069956+00:00","generated_at":"2026-05-15T04:36:33.097680+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Connect Biopharma: DMC Recommends Continue Phase 2 Asthma/COPD Trials; Topline Data Mid-2026","bullets":["DMC reviewed pre-specified interim efficacy of rademikibart (anti-IL-4Rα) in Phase 2 Seabreeze STAT trials; no sample size change.","No treatment-related serious adverse events, no severe AEs, and no discontinuations due to AEs in either study.","Topline data from both asthma and COPD studies expected in mid-2026; company plans FDA meeting for Phase 3.","CEO Barry Quart: 'Rademikibart has potential to deliver differentiated efficacy and safety in acute exacerbations.'"],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-26-000016","json":"https://secwatch.observer/filing/0001835268-26-000016.json","markdown":"https://secwatch.observer/filing/0001835268-26-000016.md","text":"https://secwatch.observer/filing/0001835268-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000016/0001835268-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000016/cntb-20260423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:36:33.097680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}